Close

BofA/Merrill Lynch Downgrades GlaxoSmithKline (GSK) to Neutral

July 28, 2014 7:50 AM EDT Send to a Friend
BofA/Merrill Lynch downgraded GlaxoSmithKline (NYSE: GSK) from Buy to Neutral with a price target of $54.00 (from $63.00) as growth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login